Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

Moderna (NASDAQ:MRNA) is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.

At a Jefferies investor session, Head of Investor Relations Lavina Talukdar said Moderna and partner Merck are advancing the biologics license application and expect to complete the filing by the end of the year. She said Moderna considers itself commercially ready, though the product has not yet been approved.

Talukdar said Moderna sees intismeran as a multibillion-dollar opportunity. For adjuvant melanoma alone, the company estimates that 22,000 U.S. patients would be eligible based on the phase III trial’s inclusion criteria. Moderna has not disclosed eligible patient populations for other potential indications.

Manufacturing and launch preparations

Moderna’s purpose-built facility in Marlborough is operating one manufacturing suite, which Talukdar said would be sufficient for commercialization in melanoma. The company plans to add up to six suites as it sees demand signals, including positive results from other studies.

At full build-out, the facility could supply tens of thousands of patients and support a global launch, Talukdar said. Moderna has not disclosed the capacity of the single operating suite.

Chief Development Officer David Berman said Moderna is focused on teaching treatment sites how to obtain and submit appropriate tumor tissue for sequencing and manufacturing. In clinical trials, turnaround time was about 63 days, partly because dosing had to be matched to pembrolizumab infusion dates. Berman said about six weeks is currently achievable, and that turnaround has reached approximately 30 days in favorable circumstances.

Manufacturing was more than 99% successful in the clinical program, Berman said. He estimated that only one of more than 700 patients assigned to the intismeran arm could not receive the product.

Talukdar said the Merck partnership provides for a 50-50 profit share. The companies will co-market intismeran in the United States, while Merck is responsible for commercialization outside the country. Moderna is still discussing how to account for sales with Merck and the companies’ auditors, she said.

Trial readouts ahead

Berman said an interim analysis in renal cell carcinoma, or RCC, could arrive around year-end or during the following year, while the final analysis in muscle-invasive bladder cancer is expected in 2027. Both studies involve intismeran.

The RCC analysis is an interim look for efficacy rather than futility, so the study will continue if the interim result does not reach statistical significance, Berman said. Moderna and Merck are discussing how they would communicate the result of the phase II interim analysis.

Berman cited the melanoma results and evidence that RCC is sensitive to T-cell-based immunotherapy among the reasons for his optimism about the kidney cancer study. He said analyses of the phase III melanoma data by tumor mutational burden, circulating tumor DNA and BRAF subgroups are in progress.

For bladder cancer, Berman said the standard of care has changed since the randomized study was designed. Moderna and Merck will consider the size of the treatment effect and the evolving treatment landscape when determining what a potential phase III study might look like.

A phase III lung cancer study that completed enrollment could produce results in late 2027 or in 2028, depending on when the required events occur, Berman said. Moderna has two other phase III studies in the adjuvant lung cancer setting.

Other pipeline and financial plans

Berman said Moderna expects myeloma data for its mRNA-2808 T-cell engager at ASH next month, followed by a readout from a pivotal trial in propionic acidemia.

Asked about a previous 2028 break-even target, Talukdar did not reiterate it. She said Moderna expects its infectious disease vaccines business to become profitable and fund its own future programs, while a balance sheet expected to be $9 billion at year-end would support oncology development.

About Moderna (NASDAQ:MRNA)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.